Citation
Walters, Arthur S., et al. "Ropinirole Is Effective in the Treatment of Restless Legs Syndrome. TREAT RLS 2: a 12-week, Double-blind, Randomized, Parallel-group, Placebo-controlled Study." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 19, no. 12, 2004, pp. 1414-23.
Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19(12):1414-23.
Walters, A. S., Ondo, W. G., Dreykluft, T., Grunstein, R., Lee, D., & Sethi, K. (2004). Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society, 19(12), 1414-23.
Walters AS, et al. Ropinirole Is Effective in the Treatment of Restless Legs Syndrome. TREAT RLS 2: a 12-week, Double-blind, Randomized, Parallel-group, Placebo-controlled Study. Mov Disord. 2004;19(12):1414-23. PubMed PMID: 15390050.
TY - JOUR
T1 - Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study.
AU - Walters,Arthur S,
AU - Ondo,William G,
AU - Dreykluft,Tilman,
AU - Grunstein,Ron,
AU - Lee,Daniel,
AU - Sethi,Kapil,
AU - ,,
PY - 2004/9/25/pubmed
PY - 2005/4/9/medline
PY - 2004/9/25/entrez
SP - 1414
EP - 23
JF - Movement disorders : official journal of the Movement Disorder Society
JO - Mov Disord
VL - 19
IS - 12
N2 - Restless legs syndrome (RLS) is a neurological condition with significant impact on sleep and quality of life (QoL). This double-blind, randomized, 12-week, multinational study compared the efficacy and safety of ropinirole and placebo in RLS. In total, 267 outpatients with moderate-to-severe RLS were randomly assigned to ropinirole (0.25-4.0 mg/day) or placebo, 1 to 3 hours before bedtime. The primary endpoint was the change in International Restless Legs Scale (IRLS) score at week 12. Key secondary endpoints were the percentage of patients showing significant improvement on the Clinical Global Impression-Improvement (CGI-I) scale at week 12 and changes in IRLS and CGI-I scale scores at week 1. Other measures included the Medical Outcomes Study sleep scale and Restless Legs Syndrome Quality of Life questionnaire. Improvements were significantly greater for ropinirole than placebo for change in IRLS score at week 12 (-11.2 [SE 0.76] vs. -8.7 [0.75], respectively; adjusted treatment difference -2.5 [95% confidence interval [CI], -4.6, -0.4], P = 0.0197); all key secondary endpoints; sleep and QoL parameters. Adverse events were typical for dopamine agonists; disease augmentation, although not directly assessed, was not reported during treatment. Ropinirole improves symptoms, associated sleep disturbance, and QoL of RLS patients and is generally well tolerated.
SN - 0885-3185
UR - https://www.unboundmedicine.com/medline/citation/15390050/Ropinirole_is_effective_in_the_treatment_of_restless_legs_syndrome__TREAT_RLS_2:_a_12_week_double_blind_randomized_parallel_group_placebo_controlled_study_
L2 - https://doi.org/10.1002/mds.20257
DB - PRIME
DP - Unbound Medicine
ER -